Five Republicans on the Senate HELP Committee urge FDA to crack down on companies they say are illegally selling chemical abortion drugs in the U.S.
FDA asks to look at Rezolute’s Phase 3 data after the company’s trial of ersodetug missed the primary endpoint, with the hope of charting a clear path forward for the stalled program.
Five Republicans on the Senate HELP Committee urge FDA to crack down on companies they say are illegally selling chemical abortion drugs in the U.S.
FDA asks to look at Rezolute’s Phase 3 data after the company’s trial of ersodetug missed the primary endpoint, with the hope of charting a clear path forward for the stalled program.
Two Hogan Lovells attorneys highlight five areas in a new FDA final guidance on weight loss devices.
Quoin Pharmaceuticals says FDA has signaled openness to a streamlined development path for its rare disease candidate QRX003, indicating that a single Phase 3 trial could be sufficient to support approval in Netherton Syndrome.
